BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatmentCNBC • 08/19/26
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's PipelinePRNewsWire • 08/18/26
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 08/14/26
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?Zacks Investment Research • 08/12/26
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-TermZacks Investment Research • 08/12/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference TranscriptSeeking Alpha • 08/12/26
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in BostonPRNewsWire • 08/10/26
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook RaisedZacks Investment Research • 08/07/26
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/06/26
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ETPRNewsWire • 07/30/26
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/27/26
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU SyndromePRNewsWire • 07/27/26
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With AchondroplasiaPRNewsWire • 07/13/26
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026PRNewsWire • 06/16/26
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/03/26
BioMarin's Voxzogo Meets Goal in Late-Stage Study for HypochondroplasiaZacks Investment Research • 05/21/26